Elanco Animal Health vs Zoetis
ELAN and ZTS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELAN and ZTS compare
Zoetis is the larger company, worth 2.9 times as much as Elanco Animal Health ($32.9B against $11.5B).
Elanco Animal Health grew revenue faster over the last twelve months (12.0% versus 1.5% for Zoetis).
Zoetis keeps more of each dollar of sales as profit, with a net margin of 27.5% compared with −4.0% at Elanco Animal Health.
Zoetis pays a dividend yielding 2.6%; Elanco Animal Health does not pay one.
Zoetis scores higher on the StockData Score (17 against 9 for Elanco Animal Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELAN | ZTS |
|---|---|---|
| Size and price | ||
| Market cap | $11.5B | $32.9B |
| Share price | $23.06 | $79.72 |
| Change, 1 year | 2.1% | −44.6% |
| Change, 5 years | −32.4% | −63.2% |
| Beta (5Y) | 1.11 | 0.78 |
| Employees | 9,400 | 15K |
| StockData Score | ||
| Total score | 9 | 17 (better) |
| Valuation score | 1 | 5 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 3 | 5 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | – | 13.1× |
| P/S | 2.3× (better) | 3.5× |
| P/B | 1.7× (better) | 10.5× |
| EV/EBITDA | 28.3× | 10.1× (better) |
| P/FCF | 30.4× | 14.2× (better) |
| PEG | – | 1.28 |
| FCF yield | 3.3% | 7.0% (better) |
| Fair value | $10.92 | $152.11 |
| Margin of safety | −111% | 47.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.0% (better) | 1.5% |
| Revenue growth, 5Y average | 7.6% (better) | 7.2% |
| Net income growth (TTM) | −146% | 0.96% (better) |
| EPS growth (TTM) | −149% | 5.6% (better) |
| EPS growth, 5Y average | – | 12.0% |
| Profitability | ||
| Gross margin | 55.4% | 71.5% (better) |
| Net margin | −4.0% | 27.5% (better) |
| FCF margin | 7.5% | 24.3% (better) |
| Return on equity | −3.0% | 64.4% (better) |
| Financial health | ||
| Debt / equity | 0.59 (better) | 2.87 |
| Net debt / EBITDA | 6.43 | 1.85 (better) |
| Current ratio | 2.05 | 3.08 (better) |
| Altman Z-score | 1.32 | 3.99 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 2.6% |
| Years of dividend growth | – | 13 |
| Dividend growth, 5Y average | – | 19.0% |
| Buyback yield | – | 11.1% |
| Shareholder yield | 0.00% | 13.7% (better) |
| Ownership | ||
| Held by institutions | 113% | 96.1% |
| Held by insiders | 1.1% | 0.08% |
| Insider net buying, 12 months | $2.6M (better) | −$1.7M |
| Superinvestors holding | – | 3 |
| Short interest, % of float | 7.5% | 4.5% |
Go deeper
- ELAN stock overview
- ELAN income statement
- ELAN valuation and score
- ZTS stock overview
- ZTS income statement
- ZTS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.